Androgen deprivation therapy induces metabolic syndrome-like effects, increasing cardiovascular risk. It is the medical oncologist's responsibility to perform a baseline CV risk assessment using tools like the STAMP questions and to engage cardiology partners when needed for risk mitigation.

While caution is necessary, a patient's prior history of pneumonitis does not automatically disqualify them from receiving an ADC with a known risk of this side effect. Clinical judgment is key; if the prior event was from a specific, known drug combination and has fully resolved, proceeding with careful monitoring can be a viable option.

An observed signal for cardiac dysfunction in the Lenvatinib-Belzutifan arm of a recent trial is causing concern among clinicians. The lack of detailed characterization for this toxicity makes it a significant point of discussion and an area requiring more data before the regimen's safety profile is fully understood.

The study utilized "interruption-free survival" as a primary endpoint, a pragmatic measure derived from real-world data. This serves as a valuable surrogate for treatment toxicity, as clinicians typically pause treatment in response to adverse events, providing a quantifiable measure of a drug's real-world tolerability.

For patients with significant comorbidities like cardiovascular disease, proactively starting lenvatinib at a reduced dose (e.g., 14mg instead of 20mg) is a practical strategy to mitigate anticipated severe toxicities from the outset.

Clinicians should avoid directly comparing the toxicity profiles of new ADCs, as the data often comes from different trial stages. A drug in a Phase 1 expansion cohort may appear more toxic than one with mature Phase 2 randomized data, making definitive safety assessments premature.

While atrial fibrillation is a well-known risk of BTK inhibitors, the more devastating and less-discussed risk is sudden death from ventricular arrhythmias. This is an 'on-target' class effect, making AFib just the 'tip of the iceberg' of cardiovascular toxicity.

While monitoring cardiac health for safety, Solid Biosciences observed a potential efficacy signal. In young patients with low-to-normal ejection fractions, the therapy appears to reverse a downward 'drift' over time, returning them to a normal range. This suggests a long-term cardioprotective benefit, even before a formal cardiomyopathy diagnosis would typically occur.

For metastatic biliary tract cancer patients with short life expectancies, oncologists are more willing to use HER2-targeted therapies despite potential cardiac dysfunction. The risk of long-term cardiotoxicity is secondary to the immediate need for an effective cancer treatment in a palliative setting.